title: [Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer].
abstract: Chemotherapy with TS-1 has recently become the first-line chemotherapy for recurrent and unresectable gastric cancer in Japan. Therefore, the establishment of a second-line chemotherapy is needed for cases that show resistance and aberrant effect to TS-1. In this study, 7 patients were treated with weekly administrations of paclitaxel after TS-1 treatment. We assessed the therapeutic effect and feasibility of chemotherapy with weekly administration of paclitaxel. Our results showed that weekly administration of paclitaxel could be a promising regimen as a second-line chemotherapy after TS-1.
authors.affiliation: Dept. of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Makari
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Takushi
authors.initials: T
authors.lastname: Yasuda
authors.forename: Shuji
authors.initials: S
authors.lastname: Takiguchi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yano
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D004487:Edema / Q000139:chemically induced; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010094:Oxonic Acid / Q000494:pharmacology; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D011725:Pyridines / Q000494:pharmacology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000494:pharmacology
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel